Free Trial

Connor Clark & Lunn Investment Management Ltd. Buys 483,698 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Amicus Therapeutics logo with Medical background

Key Points

  • Connor Clark & Lunn Investment Management Ltd. has increased its stake in Amicus Therapeutics by 159.9%, owning approximately 786,234 shares valued at $6.4 million after acquiring an additional 483,698 shares.
  • Multiple hedge funds have also increased their stakes in Amicus Therapeutics, with Nuveen Asset Management and Rock Springs Capital Management significantly raising their investments in the company during the 4th quarter.
  • Analysts have varied opinions on Amicus Therapeutics, with upgrades from Morgan Stanley and Wall Street Zen contrasting with a lowered price target from Goldman Sachs, reflecting mixed sentiments in the market.
  • Want stock alerts on Amicus Therapeutics? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 159.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 786,234 shares of the biopharmaceutical company's stock after buying an additional 483,698 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.26% of Amicus Therapeutics worth $6,416,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of FOLD. Vestal Point Capital LP purchased a new stake in shares of Amicus Therapeutics in the 4th quarter worth about $31,557,000. Orbimed Advisors LLC grew its position in Amicus Therapeutics by 300.7% during the 4th quarter. Orbimed Advisors LLC now owns 2,285,400 shares of the biopharmaceutical company's stock valued at $21,528,000 after purchasing an additional 1,715,100 shares during the last quarter. Rock Springs Capital Management LP grew its position in Amicus Therapeutics by 107.9% during the 4th quarter. Rock Springs Capital Management LP now owns 2,599,425 shares of the biopharmaceutical company's stock valued at $24,487,000 after purchasing an additional 1,349,145 shares during the last quarter. Prosight Management LP purchased a new stake in Amicus Therapeutics during the 4th quarter valued at about $8,666,000. Finally, D. E. Shaw & Co. Inc. grew its position in Amicus Therapeutics by 132.7% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,560,410 shares of the biopharmaceutical company's stock valued at $14,699,000 after purchasing an additional 889,968 shares during the last quarter.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Morgan Stanley raised shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research report on Thursday, July 17th. The Goldman Sachs Group dropped their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. UBS Group increased their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Finally, Wall Street Zen upgraded shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Amicus Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $16.22.

View Our Latest Report on Amicus Therapeutics

Amicus Therapeutics Stock Performance

NASDAQ FOLD traded up $0.28 on Friday, reaching $7.40. 4,667,819 shares of the stock were exchanged, compared to its average volume of 3,901,598. Amicus Therapeutics, Inc. has a one year low of $5.51 and a one year high of $12.65. The firm has a market capitalization of $2.28 billion, a PE ratio of -61.66 and a beta of 0.53. The company's 50-day simple moving average is $6.19 and its two-hundred day simple moving average is $7.29. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92.

About Amicus Therapeutics

(Free Report)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Further Reading

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Should You Invest $1,000 in Amicus Therapeutics Right Now?

Before you consider Amicus Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.

While Amicus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Stocks With Explosive Upside
September Slowdown: 3 Stocks to Buy When the Pullback Comes
3 Overlooked Stocks Riding the AI Data Center Boom

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines